Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline
Violette Da Cunha, Mark R Davies, Pierre-Emmanuel Douarre, Isabelle Rosinski-Chupin, Immaculada Margarit, Sebastien Spinali, Tim Perkins, Pierre Lechat, Nicolas Dmytruk, Elisabeth Sauvage, Laurence Ma, Benedetta Romi, Magali Tichit, Maria-Jose Lopez-Sanchez, Stephane Descorps-Declere, Erika Souche, Carmen Buchrieser, Patrick Trieu-Cuot, Ivan Moszer, Dominique Clermont Show all
Nature Communications | NATURE PUBLISHING GROUP | Published : 2014
Awarded by French National Research Agency
Awarded by National Health and Medical Research Council of Australia
Awarded by Wellcome Trust
Awarded by European Commission
This work was supported by the French National Research Agency (Grant ANR-08-GENM-027-001 and 2010-PATH-004-02) and by the Labex IBEID. The Institut Pasteur Genopole is a member of France Genomique (ANR10-IBNS-09-08). M. R. D. is supported by the National Health and Medical Research Council of Australia (565526 and 635250). M. T. G. H. and J.P. were supported by Wellcome Trust grant 098051. This study was in part supported by the European Commission Seventh Framework (grant agreement number 200481) as part of the DEVANI program. We would like to acknowledge Dr Sri Sriprakash and Ms Karen Taylor for their involvement with the Australian GBS strain collection and Alexandre Almeida for critical reading of the manuscript.